DongKoo Bio&Pharma Co. Ltd (006620) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of DongKoo Bio&Pharma Co. Ltd KRW 10,560, price KRW 3,520, upside +200.0%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch DongKoo Bio&Pharma Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 3,450 KRW – 9,694 KRW · fair‑value band 6,321 KRW – 14,913 KRW · the 3,520 KRW price screens below the 10,560 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow DongKoo Bio&Pharma Co. in your weekly email
Every Wednesday you see whether DongKoo Bio&Pharma Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea.
Show more
DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral, antifungal, antihistamines, antifebrile and anti-inflammatory analgesic, respiratory system, digestant, antiplatelet, other analgesics and antipyretics, nootropics and neurotonics, nonsteroidal anti-inflammatory, and oral hypoglycemic medicines; and antiphlogisnc enzyme, ophthalmic, dermatology external, and decongestants and nasal preparations, as well as non-selective a, ß-blockers and H+ pump inhibitors. It also provides cosmetic products under the CELL BLOOM brand; and SmartX, a kit-type SVF separation medical device for use in cosmetic surgery/anti-aging clinics and medical/treatments. The company was founded in 1970 and is headquartered in Seoul, South Korea.
Stock analysis
DongKoo Bio&Pharma Co. Ltd (006620) currently trades at 3,520 KRW, while our model-based Fair Value estimate is 10,560 KRW, implying the stock looks roughly 66.7% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 35,282 KRW per share, and 13 of the 15 models we run sit above the 3,520 KRW price.
Bear case: the Economic Profit group reads lowest at 2,094 KRW, and 2 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: 6,321 KRW (bear) to 14,913 KRW (bull), the price of 3,520 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
DongKoo Bio&Pharma Co. Ltd reported revenue of 243B KRW in FY2025 versus 155B KRW in FY2021, a compound +11.8%/yr. Reported net income was 50.3B KRW in FY2025, compounding +52.4%/yr from FY2021.
Key figures
Market cap 95.2B KRW (≈ $70.0M) · P/S ratio 0.51 · Dividend yield 2.2% · Net margin 20.7% · Return on equity −286% · Return on assets (EBIT) 6.1% · Operating margin 9.1% · Revenue (TTM) 187B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 41% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −41% fair-value upside, at 200%, 006620 screens cheaper than that median.
Fair Value models
Bear 6,321 KRWFair Value 10,560 KRWBull 14,913 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.47/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−2.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.8%
Start year 2020 (pandemic). Over 10 years: +11.7% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.7%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+12.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+9.8%
Dividend (yield on the price)2.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.41% vs 13%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 4%
2025 sits 676% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Compare DongKoo Bio&Pharma Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 55 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is DongKoo Bio&Pharma Co. Ltd (006620) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 10,560 KRW versus a price of 3,520 KRW, about +200% upside (undervalued).
What is the fair value of 006620?
Our model-based fair value for DongKoo Bio&Pharma Co. Ltd is 10,560 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 3,520 KRW.
What is the quality score of 006620?
DongKoo Bio&Pharma Co. Ltd has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DongKoo Bio&Pharma Co. Ltd (006620)?
Our model-based price target is the fair value of 10,560 KRW (as of Sep 24, 2026) from 15 valuation models. Cautious scenario 6,321 KRW, optimistic scenario 14,913 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the DongKoo Bio&Pharma Co. Ltd stock forecast for 2026?
Our models put fair value at 10,560 KRW, about +200% upside versus a price of 3,520 KRW (undervalued). Cautious scenario 6,321 KRW, optimistic scenario 14,913 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of DongKoo Bio&Pharma Co. Ltd (006620)?
DongKoo Bio&Pharma Co. Ltd reported trailing-twelve-month revenue of about 187B KRW (latest available figure, as of Sep 24, 2026).
Does DongKoo Bio&Pharma Co. Ltd pay a dividend?
DongKoo Bio&Pharma Co. Ltd currently shows a dividend yield of about 2.18% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of DongKoo Bio&Pharma Co. Ltd (006620)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DongKoo Bio&Pharma Co. Ltd it is 10,560 KRW per share (as of Sep 24, 2026), against a price of 3,520 KRW. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is DongKoo Bio&Pharma Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 006620 trades below its calculated fair value: price 3,520 KRW, fair value 10,560 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 006620?
No. The price is what the market pays today (3,520 KRW); the fair value is what the company's own numbers justify (10,560 KRW). For DongKoo Bio&Pharma Co. Ltd the two are 7,040 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is DongKoo Bio&Pharma Co. Ltd worth?
The market values DongKoo Bio&Pharma Co. Ltd at about 95.2B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 3,520 KRW; our models calculate a fair value of 10,560 KRW per share.
What do the bullish and bearish scenarios say about 006620?
Our models span a range for DongKoo Bio&Pharma Co. Ltd: cautious scenario 6,321 KRW, base 10,560 KRW, optimistic 14,913 KRW per share (as of Sep 24, 2026, price 3,520 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of DongKoo Bio&Pharma Co. Ltd (006620)?
Balance-sheet figures for DongKoo Bio&Pharma Co. Ltd (as of Sep 24, 2026): return on equity −286.3%, debt of 0.15 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 006620 from its 52-week high?
DongKoo Bio&Pharma Co. Ltd trades at 3,520 KRW, about 41% below its 52-week high of 5,956 KRW and 2% above the low of 3,450 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 10,560 KRW is for.
Which stocks are comparable to DongKoo Bio&Pharma Co. Ltd?
From the same area (Healthcare) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DongKoo Bio&Pharma Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 3,520 KRW, calculated fair value 10,560 KRW (+200%), Quality Score 45/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 006620 calculated?
We run DongKoo Bio&Pharma Co. Ltd through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 10,560 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. DongKoo Bio&Pharma Co. Ltd currently trades 200 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DongKoo Bio&Pharma Co. Ltd (006620)?
The closing price on Sep 23, 2026 was 3,520 KRW. Our model-based fair value is 10,560 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DongKoo Bio&Pharma Co. Ltd right now?
The price is below even our cautious bear case (6,321 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (45/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (6,321 KRW to 14,913 KRW) leaves room in how you read the outcome.
Key figures of DongKoo Bio&Pharma Co. Ltd
How large is the market capitalisation of DongKoo Bio&Pharma Co. Ltd (006620)?
The market capitalisation of DongKoo Bio&Pharma Co. Ltd is 95.2B KRW (≈ $70.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DongKoo Bio&Pharma Co. Ltd (006620)?
The price-to-sales ratio of DongKoo Bio&Pharma Co. Ltd is 0.51 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of DongKoo Bio&Pharma Co. Ltd (006620)?
The dividend yield of DongKoo Bio&Pharma Co. Ltd is 2.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DongKoo Bio&Pharma Co. Ltd (006620)?
The net margin of DongKoo Bio&Pharma Co. Ltd is 20.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DongKoo Bio&Pharma Co. Ltd (006620)?
The return on equity (ROE) of DongKoo Bio&Pharma Co. Ltd is −286% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DongKoo Bio&Pharma Co. Ltd (006620)?
On an EBIT basis the return on assets of DongKoo Bio&Pharma Co. Ltd is 6.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DongKoo Bio&Pharma Co. Ltd (006620)?
The operating margin of DongKoo Bio&Pharma Co. Ltd is 9.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DongKoo Bio&Pharma Co. Ltd (006620)?
Revenue at DongKoo Bio&Pharma Co. Ltd is growing +25.4% versus a year earlier (3y avg +7.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DongKoo Bio&Pharma Co. Ltd (006620)?
Earnings per share at DongKoo Bio&Pharma Co. Ltd are growing +35.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does DongKoo Bio&Pharma Co. Ltd (006620) generate?
The free cash flow of DongKoo Bio&Pharma Co. Ltd is −24.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does DongKoo Bio&Pharma Co. Ltd (006620) carry?
The net debt of DongKoo Bio&Pharma Co. Ltd is 106B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch DongKoo Bio&Pharma Co. Ltd in the live analysis
One click puts DongKoo Bio&Pharma Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
